查詢結果分析
相關文獻
- Targeting Brain-derived Neurotrophic Factor (BDNF) Signaling Pathway as a Treatment Strategy for Depression
- 安寧療護患者的抗憂鬱劑選擇及共同照護
- 三環類抗憂鬱藥物之血中濃度
- 抗憂鬱藥與心臟血管毒性的關係
- 憂鬱症的飛行員經治療成功後准許飛行的相關規定
- 血清素(Serotonin)症候群
- 新一代抗憂鬱藥物--選擇性血清素再回收抑制劑(Selective Serotonin Reuptake Inhibitors, SSRIs)之系統性回顧(Systematic Review)及選擇指引
- 新抗憂鬱藥Venlafaxine
- 血清素第二型受體在憂鬱症及其治療所扮演的角色
- 未接受過治療重度憂鬱症患者長程聽覺誘發波之變化
頁籤選單縮合
題名 | Targeting Brain-derived Neurotrophic Factor (BDNF) Signaling Pathway as a Treatment Strategy for Depression=腦源神經滋養因子信息路徑可能研發新型抗憂鬱藥物 |
---|---|
作者 | 蔡世仁; Tsai, Shih-jen; |
期刊 | Taiwanese Journal of Psychiatry |
出版日期 | 20180600 |
卷期 | 32:2 2018.06[民107.06] |
頁次 | 頁103-113+a2 |
分類號 | 418.214 |
語文 | eng |
關鍵詞 | 重度憂鬱症; 抗憂鬱藥; 腦源神經滋養因子; 酪氨酸激酶B; Major depressive disorders; Antidepressants; Brain-derived neurotrophic factor; BDNF; Tyrosine kinase B; |
中文摘要 | 抗憂鬱藥通常是作為憂鬱症的第一線治療選擇。然而部分的憂鬱症病人對抗憂鬱藥治療反應不佳,而且抗憂鬱藥的療效通常需使用一段時間才出現,所以憂鬱症的藥物治療對精神科醫師仍然是很大的挑戰。近二十年來的研究為憂鬱症的神經營養假說提供了有力證據,壓力及憂鬱造成海馬的腦源神經滋養因子(BDNF)減少,治療回復這個腦區的腦源神經滋養因子,並且以這個信息路徑生成新的神經細胞。這個機轉可提供一種新的治療憂鬱症的方法,達到更快的療效及治療效果。這一方面的藥物目前在動物的研究已有不錯的抗鬱效果,包括能夠增加腦源神經滋養因子生成的藥物(半胱胺,溴氰菊酯,鋅,硫化氫,鎂,S 47445, TC G-1008,丁酸鈉,肌苷,薑黃素,利魯唑,紫羅蘭鹼),激發腦源神經滋養因子受體的藥物(二異黃酮,異氟醚)和增加腦源神經滋養因子/腦源神經滋養因子前驅物比率的藥劑(阿托伐他汀,齊留通)。這些藥劑需要進一步臨床測試評估其療效及副作用,期望透過憂鬱症的神經營養假說提供抗憂鬱藥物的發展一個嶄新的方向。 |
英文摘要 | Major depressive disorder (MDD) is a common mental disorder accounting for significant morbidity and an increase in mortality worldwide. Antidepressants are often recommended as first-line treatment options in MDD patients. But the clinical management of depression with antidepressants remains a major concern for psychiatrists, and there is a need for more effective and quick onset antidepressants beyond the monoaminergic modulation. Studies in recent two decades have provided strong evidence for the neurotrophic hypothesis of MDD, suggesting that stress and antidepressant treatments exert opposing influences on the expression of brain-derived neurotrophic factor (BDNF) in the hippocampus. BDNF-mediated changes in adult hippocampal neurogenesis is critical for the therapeutic actions of antidepressant treatments. Therefore, up-regulation of BDNF signaling represents an intriguing opportunity to enhance response rates, and to have faster therapeutic onset in MDD. Those drugs that have received preclinical testing include agents that increase BDNF levels (cysteamine, deltamethrin, zinc, hydrogen sulfide, magnesium, S 47445, TC G-1008, sodium butyrate, inosine, curcumin, riluzole, and harmine), agents that activate BDNF receptors (7,8-dihydroxyflavone, and isoflurane), and agents that increase BDNF/proBDNF ratio (atorvastatin, and zileuton). The neurotrophic hypothesis of MDD may provide opportunity to develop faster and more efficient antidepressant drugs with higher response rates. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。